Gainers

• CervoMed (NASDAQ:CRVO) shares rose 133.3% to $5.79 during Tuesday's regular session. The company's market cap stands at $22.9 million.
• Neumora Therapeutics (NASDAQ:NMRA) stock rose 46.63% to $1.34. The company's market cap stands at $169.4 million.
• NewGenIvf Group (NASDAQ:NIVF) shares moved upwards by 36.95% to $0.8. The company's market cap stands at $1.6 million.
• Outlook Therapeutics (NASDAQ:OTLK) shares rose 33.62% to $1.55. The market value of their outstanding shares is at $172.3 million.
• Conexeu Sciences (NASDAQ:CNXU) shares rose 26.74% to $12.45. The market value of their outstanding shares is at $262.7 million.
• NeOnc Technologies Hldgs (NASDAQ:NTHI) shares increased by 21.84% to $5.5. The market value of their outstanding shares is at $117.3 million.

Losers

• SANUWAVE Health (NASDAQ:SNWV) shares declined by 42.0% to $8.52 during Tuesday's regular session. The market value of their outstanding shares is at $126.1 million.
• Cuprina Holdings (Cayman) (NASDAQ:CUPR) stock fell 35.64% to $5.41. The market value of their outstanding shares is at $22.5 million.
• Regentis Biomaterials (AMEX:RGNT) shares decreased by 29.92% to $6.59. The company's market cap stands at $48.6 million.
• PRF Technologies (NASDAQ:PRFX) shares decreased by 29.52% to $1.75. The company's market cap stands at $2.1 million.
• Scilex Holding (NASDAQ:SCLX) stock fell 28.94% to $5.65. The company's market cap stands at $55.9 million.
• Elicio Therapeutics (NASDAQ:ELTX) shares decreased by 28.68% to $2.91. The market value of their outstanding shares is at $77.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.